QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Sapu Nano to Present Deciparticle(TM) Nanomedicine Platform at BIO International Convention 2026
Oncotelic Therapeutics (OTCQB: OTLC) and Sapu Nano announced that Chief Executive Officer Vuong Trieu will present the Deciparticle(TM) nanomedicine platform at the BIO International Convention 2026 in San Diego, highlighting the development of ultra-small nanomedicine formulations designed to enable intravenous administration of highly water-insoluble therapeutics. The Deciparticle(TM) platform utilizes proprietary amphiphilic polymer systems capable of forming sub-20 nanometer particles for oncology and other therapeutic applications. The companies plan to showcase development progress across multiple Deciparticle(TM) programs, including Sapu006, a polysorbate-free intravenous docetaxel formulation moving into Phase 1b clinical evaluation, and Sapu003, an intravenous everolimus nanomedicine program currently in a global Phase 1b clinical trial. The presentation will also highlight the integration…